These Analysts Boost Their Forecasts On Liquidia
On Friday, the U.S. Food and Drug Administration (FDA) approved Liquidia Corporation's (NASDAQ:LQDA) Yutrepia (treprostinil) inhalation powder, a prostacyclin analog for adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise ability.
In August 2024, the FDA issued tentative approval of Yutrepia for the PAH and PH-ILD indications.
Liquidia shares fell 5.2% to trade at $14.80 on Wednesday.
These analysts made changes to their price targets on Liquidia following the announcement.
- Wells Fargo analyst Tiago Fauth maintained Liquidia with an Overweight rating and raised the price target from $20 to $23.
- HC Wainwright & Co. analyst Andrew Fein maintained the stock with a Buy and raised the price target from $29 to $35.
- Needham analyst Serge Belanger, meanwhile, reiterated Liquidia with a Buy and maintained a $25 price target.
Considering buying LQDA stock? Here’s what analysts think:
Read This Next:
- How To Earn $500 A Month From HP Stock Ahead Of Q2 Earnings
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10